Minerva Neurosciences has a quick ratio of 12.58. It generally indicates good short-term financial strength.
The historical rank and industry rank for Minerva Neurosciences's Quick Ratio or its related term are showing as below:
NERV'
s Quick Ratio Range Over the Past 10 Years
Min: 0.05 Med: 12.34 Max: 29.14
Current: 12.58
During the past 12 years, Minerva Neurosciences's highest Quick Ratio was 29.14. The lowest was 0.05. And the median was 12.34.
NERV's Quick Ratio is ranked better than 86.29% of 1554
companies
in the Biotechnology industry
Industry Median: 3.485
vs NERV: 12.58
Minerva Neurosciences Quick Ratio Historical Data
The historical data trend for Minerva Neurosciences's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Minerva Neurosciences's Quick Ratio
For the Biotechnology subindustry, Minerva Neurosciences's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Minerva Neurosciences's Quick Ratio Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Minerva Neurosciences's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Minerva Neurosciences's Quick Ratio falls into.
Minerva Neurosciences Quick Ratio Calculation
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Minerva Neurosciences's Quick Ratio for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Minerva Neurosciences (NAS:NERV) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Minerva Neurosciences Quick Ratio Related Terms
Thank you for viewing the detailed overview of Minerva Neurosciences's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Minerva Neurosciences (Minerva Neurosciences) Business Description
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It primarily focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, major depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and major depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
NERV has been successfully added to your 